What is Delfina?
Delfina provides AI-powered pregnancy care that combines predictive models, telehealth, and human support to identify maternal and fetal risk earlier.
- Category
- AI-powered maternal health
- Headquarters
- San Francisco, CA
- Founded
- 2021
- Employees
- Around 70 reported
- Total funding
- $22.3M+ raised
- Valuation
- Private, Series A
What is Delfina?
Delfina is a ai-powered maternal health company. Delfina provides AI-powered pregnancy care that combines predictive models, telehealth, and human support to identify maternal and fetal risk earlier.
Delfina provides AI-powered pregnancy care that combines predictive models, telehealth, and human support to identify maternal and fetal risk earlier. The company sells to health plans, providers, and value-based maternal-health programs that need lower-cost, proactive pregnancy care. The durable market signal is that Delfina sits close to a budget owner: security, AI platform, healthcare operations, engineering, developer productivity, or defense procurement depending on the account.
As of June 2026, the company profile is best read through product adoption, funding stage, leadership, and ecosystem partnerships rather than through public revenue, because most companies in this batch do not disclose ARR. Buyers generally evaluate Delfina on deployment risk, integration depth, compliance posture, and measurable operational impact.
Sources:DelfinaDelfina Series A
What does Delfina offer?
Delfina offers products and workflows across Pregnancy risk prediction, Care-team workflows, Telehealth support and adjacent platform capabilities.
- Pregnancy risk prediction· AI
- Care-team workflows· Healthcare
- Telehealth support· Care delivery
- Patient engagement· Mobile
- Maternal analytics· Analytics
- Population health reporting· Healthcare
Sources:DelfinaDelfina Series A
How does Delfina make money?
Revenue comes from health-plan and provider contracts for maternal care management, risk prediction, patient engagement, and clinical support.
Revenue comes from health-plan and provider contracts for maternal care management, risk prediction, patient engagement, and clinical support. Pricing is enterprise healthcare contracting rather than public per-seat pricing; contracts are tied to covered lives, care programs, implementation, and outcome commitments.
The commercial motion is enterprise-oriented: buyers pay when the platform becomes part of a production workflow, compliance program, developer process, or operational control plane. Growth is driven by more covered users or assets, deeper integrations, expansion from pilots into production, and higher support or governance requirements.
Sources:DelfinaDelfina Series A
Who leads Delfina?
Delfina is led by Senan Ebrahim, MD, PhD and Isabel Fulcher, PhD with operating leaders across product, engineering, revenue, and security or domain expertise.
- Senan Ebrahim, MD, PhDFounder and CEOFounderClinician-founder leading Delfina's maternal health strategy.
- Isabel Fulcher, PhDCo-founder and Chief Scientific OfficerFounder/current CSOBiostatistician leading predictive modeling and clinical evidence.
- Delfina clinical operations leadershipClinical operationsCurrent teamRuns care delivery and partner implementation.
How do you contact Delfina's leadership?
Delfina does not publish verified personal executive emails in the sources used for this profile, so leadership outreach should use the official route shown here unless a published direct contact exists.
isabel@delfina.com is published by NIH Seed Fund; broader personal format not verifiedSources:DelfinaDelfina Series A
How much funding has Delfina raised?
Delfina's current public funding signal is $22.3M+ raised; latest valuation/status is Not publicly disclosed.
2021: Seed - $5.3M. Story Ventures led seed funding with SemperVirens, Bread and Butter Ventures, Goodwater, and others. Jan 2025: Series A - $17M. US Venture Partners led the Series A with ARTIS Ventures, Mayo Clinic, Tokio Marine Future Fund, and existing investors.
Because Delfina is private or recently acquired, public financing data should be read as a directional capital-history snapshot, not a real-time cap table. The most reliable signal is the latest announced round or transaction, combined with hiring, product expansion, and customer-market focus.
How did Delfina get here?
Delfina's milestones show a shift from founding and early product validation into category expansion and larger enterprise or strategic relevance.
- 2021Seed fundingDelfina raises seed capital for AI-powered pregnancy care.
- 2023Scientific leadership expansionIsabel Fulcher becomes Chief Scientific Officer.
- Jan 2025Series ADelfina raises $17M to scale AI-powered maternal care.
- 2025AI 100 recognitionDelfina appears in recent AI startup recognition lists.
- 2026Population-health positioningDelfina markets predictive care for health plans and providers.
Sources:DelfinaDelfina Series A
Who are Delfina's competitors?
Delfina competes with focused startups and larger platform incumbents that already own adjacent enterprise workflows.
- Maven ClinicVirtual clinic for fertility, maternity, parenting, and menopause benefits.
- Pomelo CareVirtual maternity care provider partnering with health plans and employers.
- BabyscriptsRemote pregnancy monitoring and virtual maternity care platform.
- Oula HealthHybrid maternity clinic and virtual-care provider.
- Cayaba CareMaternal health care delivery model focused on underserved communities.
- Wildflower HealthWomen's and family health engagement platform.
Sources:DelfinaDelfina Series A
Delfina — frequently asked questions
